CO2018001831A2 - Composición de absorción percutánea en forma de parche - Google Patents
Composición de absorción percutánea en forma de parcheInfo
- Publication number
- CO2018001831A2 CO2018001831A2 CONC2018/0001831A CO2018001831A CO2018001831A2 CO 2018001831 A2 CO2018001831 A2 CO 2018001831A2 CO 2018001831 A CO2018001831 A CO 2018001831A CO 2018001831 A2 CO2018001831 A2 CO 2018001831A2
- Authority
- CO
- Colombia
- Prior art keywords
- percutaneous absorption
- absorption composition
- basic
- composition
- patch form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención se refiere a una composición de absorción percutánea que tiene una permeabilidad en la piel mejorada de un medicamento básico y un agente para promover la capacidad de absorción transdérmico de un medicamento básico. El objetivo se puede lograr por el uso de una composición de absorción percutánea que comprende un medicamento básico o una sal del mismo y ácido sórbico y/o su sal de metal. Preferiblemente, la composición de la presente invención puede además comprender un compuesto básico orgánico y/o un componente básico inorgánico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2015/074553 WO2017037813A1 (ja) | 2015-08-29 | 2015-08-29 | 塩基性薬物とソルビン酸とを含有する経皮吸収組成物 |
PCT/JP2016/075203 WO2017038767A1 (ja) | 2015-08-29 | 2016-08-29 | 経皮吸収組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018001831A2 true CO2018001831A2 (es) | 2018-05-21 |
Family
ID=58187853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0001831A CO2018001831A2 (es) | 2015-08-29 | 2018-02-22 | Composición de absorción percutánea en forma de parche |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP3342423B1 (es) |
JP (2) | JP6259117B2 (es) |
KR (1) | KR20180039622A (es) |
CN (1) | CN107427509B (es) |
BR (1) | BR112018001387B8 (es) |
CO (1) | CO2018001831A2 (es) |
ES (1) | ES2864017T3 (es) |
MX (1) | MX2018002015A (es) |
MY (1) | MY189987A (es) |
PH (1) | PH12018500271A1 (es) |
RU (1) | RU2702356C2 (es) |
SG (1) | SG11201800043UA (es) |
UA (1) | UA123212C2 (es) |
WO (2) | WO2017037813A1 (es) |
ZA (1) | ZA201800296B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11559519B2 (en) | 2018-01-31 | 2023-01-24 | Medrx, Co., Ltd. | Tizanidine therapy system |
WO2023062201A1 (en) * | 2021-10-15 | 2023-04-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system for the transdermal administration of tizanidine |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61172830A (ja) * | 1985-01-26 | 1986-08-04 | Showa Denko Kk | 皮膚外用剤組成物 |
JP4703075B2 (ja) * | 1999-07-27 | 2011-06-15 | 久光製薬株式会社 | 外用貼付剤 |
US20040142024A1 (en) * | 1999-07-27 | 2004-07-22 | Hisamitsu Pharmaceutical Co., Inc. | Patch formulation for external use |
WO2005089728A2 (en) * | 2004-03-19 | 2005-09-29 | Pfizer Health Ab | Means for transdermal administration of nicotine |
JP4807974B2 (ja) * | 2005-06-30 | 2011-11-02 | 帝國製薬株式会社 | 経皮吸収促進組成物 |
CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
CN101143127A (zh) * | 2007-10-25 | 2008-03-19 | 复旦大学 | 一种酚妥拉明外用制剂及其制备方法 |
AU2008327436B2 (en) * | 2007-11-22 | 2013-09-05 | Medrx Co., Ltd. | External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
ES2778724T3 (es) * | 2008-02-27 | 2020-08-11 | Hisamitsu Pharmaceutical Co | Parche |
JP2012158521A (ja) * | 2009-04-17 | 2012-08-23 | Kureha Corp | 外用剤 |
US9168232B2 (en) * | 2009-09-07 | 2015-10-27 | Nipro Patch Co., Ltd. | Transdermally absorbable preparation |
AU2011267348A1 (en) * | 2010-06-18 | 2012-10-25 | Merz Pharma Gmbh & Co. Kgaa | Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives |
WO2013191187A1 (ja) * | 2012-06-20 | 2013-12-27 | 株式会社メドレックス | 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物 |
-
2015
- 2015-08-29 CN CN201580078659.1A patent/CN107427509B/zh active Active
- 2015-08-29 WO PCT/JP2015/074553 patent/WO2017037813A1/ja active Application Filing
-
2016
- 2016-08-29 WO PCT/JP2016/075203 patent/WO2017038767A1/ja active Application Filing
- 2016-08-29 SG SG11201800043UA patent/SG11201800043UA/en unknown
- 2016-08-29 ES ES16841799T patent/ES2864017T3/es active Active
- 2016-08-29 UA UAA201803201A patent/UA123212C2/uk unknown
- 2016-08-29 BR BR112018001387A patent/BR112018001387B8/pt active IP Right Grant
- 2016-08-29 KR KR1020187001366A patent/KR20180039622A/ko unknown
- 2016-08-29 RU RU2018110617A patent/RU2702356C2/ru active
- 2016-08-29 MY MYPI2018700724A patent/MY189987A/en unknown
- 2016-08-29 MX MX2018002015A patent/MX2018002015A/es unknown
- 2016-08-29 JP JP2016558808A patent/JP6259117B2/ja active Active
- 2016-08-29 EP EP16841799.6A patent/EP3342423B1/en active Active
-
2017
- 2017-06-08 JP JP2017113200A patent/JP2017149782A/ja active Pending
-
2018
- 2018-01-16 ZA ZA2018/00296A patent/ZA201800296B/en unknown
- 2018-02-06 PH PH12018500271A patent/PH12018500271A1/en unknown
- 2018-02-22 CO CONC2018/0001831A patent/CO2018001831A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN107427509B (zh) | 2021-06-15 |
EP3342423A4 (en) | 2018-07-25 |
BR112018001387B8 (pt) | 2024-03-05 |
JP6259117B2 (ja) | 2018-01-10 |
ZA201800296B (en) | 2019-04-24 |
ES2864017T3 (es) | 2021-10-13 |
WO2017037813A1 (ja) | 2017-03-09 |
MX2018002015A (es) | 2018-06-19 |
PH12018500271A1 (en) | 2018-08-13 |
BR112018001387A2 (pt) | 2018-09-11 |
JPWO2017038767A1 (ja) | 2017-09-07 |
UA123212C2 (uk) | 2021-03-03 |
EP3342423B1 (en) | 2021-03-10 |
SG11201800043UA (en) | 2018-02-27 |
MY189987A (en) | 2022-03-22 |
RU2018110617A (ru) | 2019-09-30 |
RU2702356C2 (ru) | 2019-10-08 |
EP3342423A1 (en) | 2018-07-04 |
JP2017149782A (ja) | 2017-08-31 |
RU2018110617A3 (es) | 2019-09-30 |
BR112018001387B1 (pt) | 2023-09-05 |
WO2017038767A1 (ja) | 2017-03-09 |
KR20180039622A (ko) | 2018-04-18 |
CN107427509A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
CL2015002710A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
CL2014002087A1 (es) | Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal. | |
CL2015003483A1 (es) | Composiciones que comprenden tintes fotocrómicos para el tratamiento de superficies. | |
DOP2016000253A (es) | Nuevos compuestos | |
WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
NI201500118A (es) | Imidazopiridazinas sustituidas | |
CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
BR112017007864A2 (pt) | método e sistema de tratamento de uma formação subterrânea, sistema para realizar um método, composição de peso aumentado, e, método de preparo de uma composição de peso aumentado. | |
CR20160235A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
CL2015002191A1 (es) | Composición antifúngica tópica para el tratamiento de onicomicosis. | |
CO2018001831A2 (es) | Composición de absorción percutánea en forma de parche | |
BR112015021722A2 (pt) | composição para uso no tratamento de síndrome do ovário policístico | |
CR20150659A (es) | Derivados de prodroga de triazolpiridinas sustituidas |